Study of p53, BAX, and VEGF in Rectal Cancer
Author Information
Author(s): Cascinu S, Graziano F, Catalano V, Staccioli M P, Rossi M C, Baldelli A M, Barni S, Brenna A, Secondino S, Muretto P, Catalano G
Primary Institution: Division of Medical Oncology, Hospital of Parma, Italy
Hypothesis
The expression of p53, BAX, and vascular endothelial growth factor (VEGF) in node-positive rectal cancer is related to tumor recurrence and event-free survival after treatment.
Conclusion
p53 overexpression and VEGF positivity are associated with worse event-free survival and higher recurrence rates in patients with node-positive rectal cancer.
Supporting Evidence
- 39 patients remained disease-free while 40 patients relapsed after treatment.
- Local relapses were more frequent in patients with p53 overexpressing tumors.
- Distant metastases were associated with vascular endothelial growth factor positive tumors.
- Patients with p53 negative or VEGF negative tumors had better event-free survival.
Takeaway
This study looked at how certain proteins in rectal cancer tumors can help predict if patients will get better or have their cancer come back after treatment.
Methodology
The study analyzed tumor samples from patients who underwent surgery for stage III rectal cancer, focusing on the expression of p53, BAX, and VEGF using immunohistochemistry.
Potential Biases
Potential biases from the retrospective nature of the study and the inability to distinguish between wild-type and mutated p53.
Limitations
The study is retrospective and may have biases related to the immunohistochemical analysis of p53.
Participant Demographics
Patients with node-positive rectal cancer who underwent curative surgery between 1994 and 1996.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website